Current Medical Issues

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 20  |  Issue : 3  |  Page : 130--137

Outcomes of supraflex Sirolimus-eluting coronary stents


Vishal Virendra Singh1, Sheikh Mohamad Tahir2, Sanjiv Sharma3 
1 Department of Cardiology, Apusnova Multi-Super Speciality Hospital, Meerut, Uttar Pradesh, India
2 Department of Cardiology, Super Speciality Hospital, GMC, Srinagar, Jammu and Kashmir, India
3 Batra Hospital and Medical Research Centre, New Delhi, India

Correspondence Address:
Dr. Sheikh Mohamad Tahir
Super Speciality Hospital, GMC, Srinagar, Jammu and Kashmir
India

Background: The development of a sirolimus-eluting coronary stent (SES) was a big step forward in interventional cardiology. SES has been demonstrated in large, randomized clinical studies to reduce angiographic restenosis and target vessel revascularization (TVR) when compared to bare-metal stents and other drug-eluting stents (DESs). However, there is little information on the outcomes of Indian patients treated with Drug-eluting stents (DES). As a result, the study's goal was to assess the efficacy of Supraflex sirolimus-eluting coronary stents in the treatment of coronary artery disease and to identify severe adverse cardiovascular and cerebrovascular events. Methods: This single-center, observational, nonrandomized study enrolled unselected real-world patients at a tertiary care center who had undergone implantation with Supraflex sirolimus-eluting stents. The primary endpoint of the study was major adverse cardiovascular and cerebrovascular events (MACCE), which is a conglomeration of cardiac death, target lesion revascularization, TVR, cerebrovascular accident (CVA), and heart failure at 1-year follow-up. Results: A total of 100 patients were intervened successfully with sirolimus-eluting stents. Out of total patients, diabetes and hypertension were observed in 38% and 35% of patients, respectively. According to the American College of Cardiology/American Heart Association classification, there were 68% of type B lesions and 32% of type C lesions. At 1-year follow-up, major adverse cardiovascular events were 11%, a composite of 4% target lesion revascularization, 3% target vessel revascularization, 1% CVA, and 5% heart failure. Diabetes (P = 0.02), hypertension (P = 0.01), kidney dysfunction (P = 0.002), and left ventricular (LV) function (P = 0.01) strongly correlated with outcome (MACCE). Conclusion: There was an acceptable rate of adverse events after implantation of the Supraflex sirolimus-eluting stents, although slightly higher than in other studies. Diabetes, hypertension, kidney dysfunction, and LV function strongly correlate with the outcome (MACCE).


How to cite this article:
Singh VV, Tahir SM, Sharma S. Outcomes of supraflex Sirolimus-eluting coronary stents.Curr Med Issues 2022;20:130-137


How to cite this URL:
Singh VV, Tahir SM, Sharma S. Outcomes of supraflex Sirolimus-eluting coronary stents. Curr Med Issues [serial online] 2022 [cited 2022 Aug 9 ];20:130-137
Available from: https://www.cmijournal.org/article.asp?issn=0973-4651;year=2022;volume=20;issue=3;spage=130;epage=137;aulast=Singh;type=0